Study title: HX181-Appréciation en ouvert de l'activité et de la tolérance héxomedine solution chez l'enfant (dossier de modification de formule du 30/10/87) -partie IVB - Paupe and Prost - 27/04/1986Kettelhut, B. V., Berkebile, C., Bradley, D., and Metcalfe, D. D. Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Disease, Bethesda, Md 20892 A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis J.Allergy Clin.Immunol. 1989;83:866-870.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Skin and Connective Tissue Diseases [C17] | |||||
| Brands: | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: HEXAMIDINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: report ref. : HX/182 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |